Drug Development

Feliza Mirasol is the science editor for 

Articles

There is need for training personnel in various analytical skill sets for biologic drug substance testing.

Biologics Testing Highlights Need for Analytical Skills

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Increased patient-centricity and alternative dosage forms require careful consideration when selecting the best taste-masking approach.

It’s a Matter of Taste-Masking

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Polymeric amorphous solid dispersions are the most commonly used technology, but amorphous APIs remain inherently unstable.

Stabilization of Amorphous APIs

EMA has fully validated the marketing authorization application for Atara Biotherapeutics’ off-the-shelf allogeneic T-cell therapy, tab-cel (tabelecleucel), with an approval decision expected in 2022.

Atara Biotherapeutics' MAA for Allogeneic T-cell Immunotherapy Gets EMA Validation

Chinook Therapeutics has formed a 50/50 joint venture with investors to develop kidney disease therapies in China.

Chinook Therapeutics and Investors Form Joint Venture for Kidney Disease Therapies

BeiGene has acquired property in Hopewell, NJ to build a new manufacturing site and clinical R&D center for advanced new medicines.

BeiGene Acquires Property in New Jersey to Build Manufacturing and Clinical R&D Center

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp. have partnered to advance GreenLight’s mRNA COVID-19 vaccine candidate.

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp to Build mRNA Vaccine Manufacturing Capacity

Secarna Pharmaceuticals and Achilles Therapeutics have entered into an agreement to optimize the development of T cell therapies in Achilles’ pipeline.

Secarna Pharmaceuticals and Achilles Therapeutics Partner on T Cell Therapy Development

CGT Catapult and Deep Science Ventures have partnered to encourage innovative approaches to overcoming barriers in delivering advance therapies to patients.

CGT Catapult and Deep Science Ventures Team Up to Boost Innovation in Advanced Therapies

Under the expanded agreement with Agios, Centogene will provide global clinical trial support for thalassemia and sickle cell diseases.

APIs and Excipients